Early detection of cardiovascular-renal-metabolic conditions: from silent to seen

Building on recent and upcoming global commitments on these interconnected conditions, the session will bring together perspectives from the advocacy sector, academia, governments, and industry to explore practical actions for countries to drive integrated CRM care for patients. There will be a particular focus on improving early screening and diagnosis of chronic kidney disease (CKD) and steatotic liver disease (SLD), which are often silent until advanced stages and co-exist with and amplify other CRM conditions.